DART partner Optellum has attained CE marking in Europe.
This latest certification will allow for use in the European Union (EU) and the United Kingdom (UK), and opens the door to a European expansion for the growing company. It is the latest milestone for Optellum, which received FDA 510(k) clearance in early 2021 as the first AI-assisted diagnosis application for lung cancer. You can read the full press release online here.
In addition, researchers from the University of Oxford and Oxford University Hospitals NHS Foundation Trust (OUH) have published the results of an academic study in European Radiology which takes a closer look at the Optellum Lung Cancer Prediction (LCP) model. You can read the full story on Optellum’s website here.
Unlocking the future of lung cancer screening: How DART is redefining early diagnosis
October 23, 2023
When it comes to the battle against lung cancer, early detection is the key to saving lives. But what if…
Comparing imaging techniques to diagnose lung cancer – looking for advisors
May 25, 2023
CanPredict: Lung cancer risk prediction
April 13, 2023
February 27, 2023